Type:
Educational Exhibit
Keywords:
Interventional non-vascular, Lung, Oncology, CT, Biopsy, Chemotherapy, Neoplasia, Pathology
Authors:
R. Chaganti, C. Zhou, J. Hanson
DOI:
10.26044/ranzcr2022/R-0195
References
[1] Lee KH, Lim KY, Suh YJ et al. Nondiagnostic Percutaneous Transthoracic Needle Biopsy of Lung Lesions: A Multicenter Study of Malignancy Risk. Radiology 2019; 290:814–823.
[2] Yoon HJ, Lee HY, Lee KS et al. Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications. Radiology 2012; 265:939-948.
[3] Tam AL, Kim ES, Lee JJ et al. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol 2013; 8: 436-442.
[4] Tsai EB, Pomykala K, Ruchalski K et al. Feasibility and safety of intrathoracic biopsy and repeat biopsy for evaluation of programmed cell death ligand-1 expression for immunotherapy in non small-cell lung cancer. Radiology 2018; 287: 326-332.
[5] Callister MEJ, Baldwin DR, Akram AR et al. BTS guidelines for the investigation and management of pulmonary nodules. Thorax 2015; 70: ii1-ii54.
[6] Huang MD, Weng HH, Hsu SL et al. Accuracy and complications of CT-guided pulmonary core biopsy in small nodules: a single-center experience. Cancer Imaging 2019; 19: 51.
[7] Fontaine-Delaruelle C, Souquet PJ, Gamondes D et al. Negative predictive value of transthoracic core-needle biopsy: a multicenter study. Chest 2015; 148(2): 472-480.
[8] Bankier AA, MacMahon H, Goo JM et al. Recommendations for Measuring Pulmonary Nodules at CT: A Statement from the Fleischner Society. Radiology. 2017; Nov 285(2):584-600.